Please login to the form below

Not currently logged in
Email:
Password:

FDA moves to tackle orphan designation backlog

Some 200 requests are awaiting review by the US regulator

FDA

The US Food and Drug Administration (FDA) has unveiled its plans to eliminate a backlog of orphan drug designation requests that currently numbers around the 200 mark.

The US regulator's Orphan Drug Modernisation Plan aims to eliminate the waiting list, and is the first development under the FDA's new Medical Innovation Development Plan.

The move comes just one week after FDA commissioner Scott Gottlieb vowed to eradicate the backlog within 90 days (giving his agency a mid-September target), and said he wanted all new requests for designation to have a response within 90 days of receipt.

To ensure this, the agency’s latest plan will take a multifaceted approach and these efforts will include a re-organisation of review staff, better leveraging the experience across medical product centres and establishing a new FDA Orphan Products Council, which will address scientific and regulatory issues.

“People who suffer with rare diseases are too often faced with no, or limited, treatment options, and what treatment options they have may be quite expensive due in part to significant costs of developing therapies for smaller populations,” said Gottlieb.

“Congress gave us tools to incentivise the development of novel therapies for rare diseases and we intend to use these resources to their fullest extent in order to ensure Americans get the safe and effective medicines they need, and that the process for developing these innovations is as modern and efficient as possible.”

There are currently about 200 orphan drug designation requests that are pending review and as result, the agency plans to deploy a backlog team compromised of senior reviewers with experience in orphan drug designation to solely focus on the backlogged applications, starting with the oldest requests.

A designation review template will also be implemented to increase consistency and efficiency on the agency’s reviews and will look to collaborate within the FDA’s medical product centres.

Article by
Gemma Jones

3rd July 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics